全文获取类型
收费全文 | 2718篇 |
免费 | 256篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 138篇 |
妇产科学 | 66篇 |
基础医学 | 332篇 |
口腔科学 | 123篇 |
临床医学 | 325篇 |
内科学 | 657篇 |
皮肤病学 | 37篇 |
神经病学 | 215篇 |
特种医学 | 130篇 |
外科学 | 262篇 |
综合类 | 91篇 |
一般理论 | 2篇 |
预防医学 | 310篇 |
眼科学 | 34篇 |
药学 | 102篇 |
中国医学 | 6篇 |
肿瘤学 | 128篇 |
出版年
2022年 | 23篇 |
2021年 | 63篇 |
2020年 | 29篇 |
2019年 | 39篇 |
2018年 | 45篇 |
2017年 | 39篇 |
2016年 | 33篇 |
2015年 | 60篇 |
2014年 | 60篇 |
2013年 | 99篇 |
2012年 | 130篇 |
2011年 | 118篇 |
2010年 | 78篇 |
2009年 | 67篇 |
2008年 | 99篇 |
2007年 | 108篇 |
2006年 | 115篇 |
2005年 | 133篇 |
2004年 | 99篇 |
2003年 | 93篇 |
2002年 | 88篇 |
2001年 | 83篇 |
2000年 | 97篇 |
1999年 | 72篇 |
1998年 | 61篇 |
1997年 | 32篇 |
1996年 | 42篇 |
1995年 | 25篇 |
1994年 | 40篇 |
1993年 | 29篇 |
1992年 | 48篇 |
1991年 | 55篇 |
1990年 | 56篇 |
1989年 | 58篇 |
1988年 | 53篇 |
1987年 | 68篇 |
1986年 | 59篇 |
1985年 | 47篇 |
1984年 | 35篇 |
1983年 | 25篇 |
1982年 | 22篇 |
1981年 | 19篇 |
1980年 | 18篇 |
1979年 | 26篇 |
1978年 | 18篇 |
1976年 | 25篇 |
1974年 | 23篇 |
1972年 | 18篇 |
1971年 | 19篇 |
1970年 | 21篇 |
排序方式: 共有2983条查询结果,搜索用时 15 毫秒
71.
Alexander Breitenstein Susanna H. M. Sluka Alexander Akhmedov Simona Stivala Jan Steffel Giovanni G. Camici Huy H. Riem Hans-Jurg Beer Jan-Dirk Studt Firat Duru Thomas F. Luscher Felix C. Tanner 《Basic research in cardiology》2012,107(6):1-8
Dronedarone has been associated with a reduced number of first hospitalisation due to acute coronary syndromes. Whether this is only due to the reduction in ventricular heart rate and blood pressure or whether other effects of dronedarone may be involved is currently elusive. This study was designed to investigate the role of dronedarone in arterial thrombus formation. C57Bl/6 mice were treated with dronedarone and arterial thrombosis was investigated using a mouse photochemical injury model. Dronedarone inhibited carotid artery thrombus formation in vivo (P?<?0.05). Thrombin- and collagen-induced platelet aggregation was impaired in dronedarone-treated mice (P?<?0.05), and expression of plasminogen activator inhibitor-1 (PAI1), an inhibitor of the fibrinolytic system, was reduced in the arterial wall (P?<?0.05). In contrast, the level of tissue factor (TF), the main trigger of the coagulation cascade, and that of its physiological inhibitor, TF pathway inhibitor, did not differ. Similarly, coagulation times as measured by prothrombin time and activated partial thromboplastin time were comparable between the two groups. Dronedarone inhibits thrombus formation in vivo through inhibition of platelet aggregation and PAI1 expression. This effect occurs within the range of dronedarone concentrations measured in patients, and may represent a beneficial pleiotropic effect of this drug. 相似文献
72.
A. H. V. Schapira P. Barone R. A. Hauser Y. Mizuno O. Rascol M. Busse C. Debieuvre M. Fraessdorf W. Poewe for the Pramipexole ER Studies Group 《European journal of neurology》2013,20(1):50-56
Background and purpose: In chronic diseases including Parkinson’s disease (PD), complex pharmacotherapy dosing schedules are reported to reduce adherence, perhaps leading to less‐effective symptom control and, in PD, more erratic stimulation of dopamine receptors. However, blinded clinical‐trial designs preclude direct comparisons of adherence to various schedules. Methods: In two double‐blind (DB) studies of early PD and one of advanced PD, subjects received three‐times‐daily (t.i.d.) pramipexole or placebo. In open‐label (OL) extensions, subjects took extended‐release, once‐daily (q.d.) pramipexole. At 24 or 32 OL weeks, q.d. versus t.i.d. dosing preference was surveyed by questionnaire. Results: Of 590 DB‐trial completers with early PD, 511 entered the OL extension. Of 374 survey respondents, 94.4% preferred q.d. dosing (72.2% of them found it ‘very much more convenient’ and 27.8%‘more convenient’), 2.7% preferred t.i.d., and 2.9% chose ‘no difference’. Of 465 DB‐trial completers with advanced PD, 391 entered its OL extension. Of 334 survey respondents, 88.9% preferred q.d. dosing (59.9% of them found it ‘very much more convenient’ and 40.1%‘more convenient’), 5.7% preferred t.i.d., and 5.4% chose ‘no difference’. Results excluding DB‐placebo recipients were highly similar. Conclusions: In this first direct comparison of patient preference for q.d. versus t.i.d. dopamine‐agonist dosing, patients with early or advanced PD had a strong preference for q.d. rather than t.i.d. pramipexole. The high proportion of advanced‐PD patients declaring this preference indicates that it does not depend on whether a patient is taking concomitant PD medications dosed more frequently than q.d. 相似文献
73.
Helen A. Fletcher Rachel Tanner Robert S. Wallis Joel Meyer Zita-Rose Manjaly Stephanie Harris Iman Satti Richard F. Silver Dan Hoft Beate Kampmann K. Barry Walker Hazel M. Dockrell Uli Fruth Lew Barker Michael J. Brennan Helen McShane 《Clinical and Vaccine Immunology : CVI》2013,20(11):1683-1689
Despite the widespread use of the Mycobacterium bovis BCG vaccine, there are more than 9 million new cases of tuberculosis (TB) every year, and there is an urgent need for better TB vaccines. TB vaccine candidates are selected for evaluation based in part on the detection of an antigen-specific gamma interferon (IFN-γ) response. The measurement of mycobacterial growth in blood specimens obtained from subjects immunized with investigational TB vaccines may be a better in vitro correlate of in vivo vaccine efficacy. We performed a clinical study with 30 United Kingdom adults who were followed for 6 months to evaluate the abilities of both a whole-blood- and a novel peripheral blood mononuclear cell (PBMC)-based mycobacterial growth inhibition assay to measure a response to primary vaccination and revaccination with BCG. Using cryopreserved PBMCs, we observed a significant improvement in mycobacterial growth inhibition following primary vaccination but no improvement in growth inhibition following revaccination with BCG (P < 0.05). Mycobacterial growth inhibition following primary BCG vaccination was not correlated with purified protein derivative (PPD) antigen-specific IFN-γ enzyme-linked immunospot (ELISPOT) responses. We demonstrate that a mycobacterial growth inhibition assay can detect improved capacity to control growth following primary immunization, but not revaccination, with BCG. This is the first study to demonstrate that an in vitro growth inhibition assay can identify a difference in vaccine responses by comparing both primary and secondary BCG vaccinations, suggesting that in vitro growth inhibition assays may serve as better surrogates of clinical efficacy than the assays currently used for the assessment of candidate TB vaccines. 相似文献
74.
75.
76.
77.
AC Tanner AL Sonis P Lif Holgerson JR Starr Y Nunez CA Kressirer BJ Paster I Johansson 《Journal of dental research》2012,91(9):853-858
White-spot lesions (WSL) associated with orthodontic appliances are a cosmetic problem and increase risk for cavities. We characterized the microbiota of WSL, accounting for confounding due to gingivitis. Participants were 60 children with fixed appliances, aged between 10 and 19 yrs, half with WSL. Plaque samples were assayed by a 16S rRNA-based microarray (HOMIM) and by PCR. Mean gingival index was positively associated with WSL (p = 0.018). Taxa associated with WSL by microarray included Granulicatella elegans (p = 0.01), Veillonellaceae sp. HOT 155 (p < 0.01), and Bifidobacterium Cluster 1 (p = 0.11), and by qPCR, Streptococcus mutans (p = 0.008) and Scardovia wiggsiae (p = 0.04) Taxa associated with gingivitis by microarray included: Gemella sanguinis (p = 0.002), Actinomyces sp. HOT 448 (p = 0.003), Prevotella cluster IV (p = 0.021), and Streptococcus sp. HOT 071/070 (p = 0.023); and levels of S. mutans (p = 0.02) and Bifidobacteriaceae (p = 0.012) by qPCR. Species' associations with WSL were minimally changed with adjustment for gingivitis level. Partial least-squares discriminant analysis yielded good discrimination between children with and those without WSL. Granulicatella, Veillonellaceae and Bifidobacteriaceae, in addition to S. mutans and S. wiggsiae, were associated with the presence of WSL in adolescents undergoing orthodontic treatment. Many taxa showed a stronger association with gingivitis than with WSL. 相似文献
78.
79.
Christopher G. Goetz MD Glenn T. Stebbins PhD Kathryn A. Chung MD Robert A. Hauser MD MBA Janis M. Miyasaki MD Anthony P. Nicholas MD PhD Werner Poewe MD Klaus Seppi MD Olivier Rascol MD PhD Mark A. Stacy MD John G. Nutt MD Caroline M. Tanner MD PhD Alison Urkowitz MPA Jean A. Jaglin RN Song Ge MS 《Movement disorders》2013,28(3):341-346
Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo‐controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang‐Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26‐Item Parkinson's Disease Dyskinesia scale (PDD‐26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), and Clinical Global Impression (severity and change: CGI‐S, CGI‐C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty‐one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI‐C, LF, PDD‐26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (η2 = 0.138) for detecting treatment‐related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. © 2012 Movement Disorder Society 相似文献
80.
Männikkö Niko Mustonen Terhi Tanner Niina Vähänikkilä Hannu Kääriäinen Maria 《International journal of mental health and addiction》2022,20(5):2956-2972
International Journal of Mental Health and Addiction - Excessive digital gaming can have unfavorable effects on gamers’ well-being and everyday functioning. The aims of this study were to... 相似文献